Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi

Sep 28 2021

• By Joseph Haas

Pills on Hiv - aids background — ViiV looks ahead with third-gen integrase inhibitor from Shionogi

Related Content

Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV

Oct 29 2012

Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

Nov 09 2020

ASH Data Bring UniQure Closer To Filing Hemophilia B Gene Therapy

Nov 19 2020

ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"

Apr 09 2019

ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology

Jun 22 2021

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

Jan 22 2021

Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment

Mar 15 2021

Related Companies

ViiV Healthcare

GSK plc

Shionogi & Co. Ltd.

Pfizer Inc.

Johnson & Johnson

Gilead Sciences, Inc.

Merck & Co., Inc.

Halozyme Therapeutics, Inc.

Additional Topics

Deals Business Strategies Commercial Research & Development Infectious Diseases BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window